Codagenix is a later-stage private company working in the vaccine and cancer virotherapeutic space using a machine learning platform to rationally redesign viral genomes to reduce viral gene function. Their most advanced program is an intranasal COVID vaccine currently in a Phase 3 trial sponsored by the World Health Organization. Other clinical-stage programs include RSV, which recently reveived FDA Breakthrough Designation, and universal influenza, along with an IND-ready oncolytic virus, and preclinical programs in dengue and yellow fever.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
New York
Company HQ Country:
United States
Year Founded:
2009
Main Therapeutic Focus:
Infectious Diseases
Lead Product in Development:
CoviLiv
Development Phase of Primary Product:
Phase III
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
